Cargando…

Circulating ACE2: a novel biomarker of cardiovascular risk

Detalles Bibliográficos
Autores principales:	Ramchand, Jay, Burrell, Louise M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529379/ https://www.ncbi.nlm.nih.gov/pubmed/33010824 http://dx.doi.org/10.1016/S0140-6736(20)32011-0

Ejemplares similares

ACE2 expression and sex disparity in COVID-19
por: Gagliardi, Maria Cristina, et al.
Publicado: (2020)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular Hypertrophy
por: Patel, Sheila K., et al.
Publicado: (2018)

Novel Approach to Risk Stratification in Left Ventricular Non‐Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach
por: Ramchand, Jay, et al.
Publicado: (2021)

Cardiovascular risks of climate change
por: Peters, Annette, et al.
Publicado: (2020)

Targeting ACE2 as a potential prophylactic strategy against COVID-19-induced exacerbation of chronic kidney disease
por: Kazama, Itsuro
Publicado: (2022)

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease
por: Ramchand, Jay, et al.
Publicado: (2018)

Novel biomarkers of childhood and adolescent obesity
por: Yanes Cardozo, Licy L., et al.
Publicado: (2021)

Biomarkers for cardiovascular risk prediction: from pioneering to evidence-based use in clinical practice
por: Hemels, M. E. W.
Publicado: (2022)

Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition
por: Velkoska, Elena, et al.
Publicado: (2009)

Circulating ACE2 activity correlates with cardiovascular disease development
por: Úri, Katalin, et al.
Publicado: (2016)

Plasma Angiotensin Converting Enzyme 2 (ACE2) Activity in Healthy Controls and Patients with Cardiovascular Risk Factors and/or Disease
por: Lim, Hui Yin, et al.
Publicado: (2022)

Predicted but not destined: considerations for obesity-related cardiovascular risk projection
por: Wang, Tzung-Dau, et al.
Publicado: (2023)

Cardiovascular risks in subjects exposed to the Brumadinho dam collapse, Minas Gerais, Brazil
por: Valenti, Vitor Engrácia, et al.
Publicado: (2019)

Reducing cardiovascular risk caused by air pollution: individuals can make a difference
por: Mahlof, Elliot N., et al.
Publicado: (2020)

Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15
por: Patel, Sheila K., et al.
Publicado: (2018)

Hyperoxia during venoarterial ECMO: Culprit or co-variate? A comment from the BLENDER investigators
por: Premraj, Lavienraj, et al.
Publicado: (2022)

ACE2, a new regulator of the renin–angiotensin system
por: Burrell, Louise M., et al.
Publicado: (2004)

Comments: Absolute cardiovascular risk assessment for guiding antihypertensive prescribing in Australian primary care patients with hypertension
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2022)

Inter-arm blood pressure difference, when is it a useful risk marker for cardiovascular events?
por: Clark, Christopher E.
Publicado: (2021)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Digital biomarkers: Convergence of digital health technologies and biomarkers
por: Vasudevan, Srikanth, et al.
Publicado: (2022)

Beclin1 circulating levels and accelerated aging markers in COPD
por: Schlemmer, Frédéric, et al.
Publicado: (2018)

The elusive biomarker
por: Huntingford, Simone, et al.
Publicado: (2022)

COVID-19 and the cardiovascular system
por: Zheng, Ying-Ying, et al.
Publicado: (2020)

Big bottlenecks in cardiovascular tissue engineering
por: Huang, Ngan F., et al.
Publicado: (2018)

Designing circulating tumor DNA-based interventional clinical trials in oncology
por: Araujo, Daniel V., et al.
Publicado: (2019)

Long COVID — metabolic risk factors and novel therapeutic management
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Arterial function and cardiovascular risk in dialysis
por: Iorio, Biagio R Di, et al.
Publicado: (2015)

Type 2 alveolar epithelial cell-derived circulating extracellular vesicle-encapsulated surfactant protein C as a mediator of cardiac inflammation in COVID-19
por: Rudiansyah, Mohammad, et al.
Publicado: (2022)

LC-MS biomarker diagnostics for neuroinflammatory disorders
por: Morrens, M., et al.
Publicado: (2022)

Digital biomarkers in human excreta
por: Park, Seung-min, et al.
Publicado: (2021)

Tackling cardiovascular health inequalities in European countries
por: Bugiardini, Raffaele
Publicado: (2023)

Cardiovascular health and disease in migrant populations: a call to action
por: Agyemang, Charles, et al.
Publicado: (2021)

Should ethnicity be included in cardiovascular risk stratification?
por: Krenning, B. J., et al.
Publicado: (2014)

Pokémon Go: cardiovascular benefit or injury risk?
por: Sharma, Pranev, et al.
Publicado: (2016)

Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections
por: Epstein, Jay, et al.
Publicado: (2020)

Neuron navigator 2 is a novel mediator of rheumatoid arthritis
por: Wang, Ran, et al.
Publicado: (2021)

Increased cardiovascular mortality in African Americans with COVID-19
por: McGonagle, Dennis, et al.
Publicado: (2020)

Strategies to prevent burnout in the cardiovascular health-care workforce
por: Mehta, Laxmi S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n3r65pj51ltdlrrknjm1lpcj4b